Allarity Therapeutics Stock Performance
| ALLR Stock | USD 0.97 0.03 2.50% |
The firm shows a Beta (market volatility) of 1.92, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Allarity Therapeutics will likely underperform. At this point, Allarity Therapeutics has a negative expected return of -0.31%. Please make sure to confirm Allarity Therapeutics' value at risk, as well as the relationship between the daily balance of power and price action indicator , to decide if Allarity Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Allarity Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with inconsistent performance in the last few months, the Stock's essential indicators remain relatively invariable which may send shares a bit higher in March 2026. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Last Split Factor 1:30 | Last Split Date 2024-09-11 |
1 | Exit strategy if youre trapped in Allarity Therapeutics Inc. - Quarterly Growth Report Expert Curated Trade Setups - newser.com | 11/07/2025 |
2 | How Allarity Therapeutics Inc. stock reacts to oil prices - 2025 Valuation Update AI Powered Market Trend Analysis - newser.com | 11/10/2025 |
3 | Why Allarity Therapeutics Inc. stock appeals to analysts - 2025 Price Targets Safe Entry Point Identification - newser.com | 11/13/2025 |
4 | Real time breakdown of Allarity Therapeutics Inc. stock performance - 2025 Key Lessons Weekly Top Gainers Alerts - newser.com | 11/18/2025 |
5 | Allarity Therapeutics Inc to offer up to 50 million in securities - MarketScreener | 12/03/2025 |
6 | ALLR Ascendiant Capital Raises Price Target, Maintains Buy Rating ALLR Stock News - GuruFocus | 12/09/2025 |
7 | Allarity Therapeutics Completes Additional Private Equity Financing - TipRanks | 12/23/2025 |
8 | Acquisition by Jeremy Graff of 133333 shares of Allarity Therapeutics subject to Rule 16b-3 | 01/07/2026 |
9 | Market Wrap What dividend safety score for Allarity Therapeutics Inc stock - Quarterly Performance Summary Technical Confirmation Alerts - moha.gov.vn | 01/09/2026 |
10 | Allarity Therapeutics Secures Flexible Equity Financing Facility - TipRanks | 01/29/2026 |
| Begin Period Cash Flow | 166 K | |
| Total Cashflows From Investing Activities | -298 K |
Allarity Therapeutics Relative Risk vs. Return Landscape
If you would invest 123.00 in Allarity Therapeutics on November 4, 2025 and sell it today you would lose (27.99) from holding Allarity Therapeutics or give up 22.76% of portfolio value over 90 days. Allarity Therapeutics is currently does not generate positive expected returns and assumes 4.5414% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than Allarity, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Allarity Therapeutics Target Price Odds to finish over Current Price
The tendency of Allarity Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.98 | 90 days | 0.98 | under 95 |
Based on a normal probability distribution, the odds of Allarity Therapeutics to move above the current price in 90 days from now is under 95 (This Allarity Therapeutics probability density function shows the probability of Allarity Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.92 . This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Allarity Therapeutics will likely underperform. Additionally Allarity Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Allarity Therapeutics Price Density |
| Price |
Predictive Modules for Allarity Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Allarity Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Allarity Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Allarity Therapeutics is not an exception. The market had few large corrections towards the Allarity Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Allarity Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Allarity Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.41 | |
β | Beta against Dow Jones | 1.92 | |
σ | Overall volatility | 0.11 | |
Ir | Information ratio | -0.08 |
Allarity Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Allarity Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Allarity Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Allarity Therapeutics generated a negative expected return over the last 90 days | |
| Allarity Therapeutics has some characteristics of a very speculative penny stock | |
| Allarity Therapeutics has high historical volatility and very poor performance | |
| Allarity Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Allarity Therapeutics currently holds 1.35 M in liabilities with Debt to Equity (D/E) ratio of 0.11, which may suggest the company is not taking enough advantage from borrowing. Allarity Therapeutics has a current ratio of 0.86, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Allarity Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (24.52 M) with loss before overhead, payroll, taxes, and interest of (36.35 M). | |
| Allarity Therapeutics currently holds about 7.73 M in cash with (17.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.75. | |
| Allarity Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Allarity Therapeutics Secures Flexible Equity Financing Facility - TipRanks |
Allarity Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Allarity Stock often depends not only on the future outlook of the current and potential Allarity Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Allarity Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.6 M | |
| Cash And Short Term Investments | 19.5 M |
Allarity Therapeutics Fundamentals Growth
Allarity Stock prices reflect investors' perceptions of the future prospects and financial health of Allarity Therapeutics, and Allarity Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Allarity Stock performance.
| Return On Equity | -1.51 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | 1.3 M | ||||
| Shares Outstanding | 14.52 M | ||||
| Price To Book | 1.40 X | ||||
| Gross Profit | (36.35 M) | ||||
| EBITDA | (24.23 M) | ||||
| Net Income | (24.52 M) | ||||
| Cash And Equivalents | 7.73 M | ||||
| Cash Per Share | 0.75 X | ||||
| Total Debt | 1.35 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 0.88 X | ||||
| Book Value Per Share | 0.83 X | ||||
| Cash Flow From Operations | (17.35 M) | ||||
| Earnings Per Share | 5.75 X | ||||
| Market Capitalization | 17.28 M | ||||
| Total Asset | 22.65 M | ||||
| Retained Earnings | (118.97 M) | ||||
| Working Capital | 11.5 M | ||||
About Allarity Therapeutics Performance
Assessing Allarity Therapeutics' fundamental ratios provides investors with valuable insights into Allarity Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Allarity Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 24.99 | 22.21 | |
| Return On Tangible Assets | (0.97) | (1.02) | |
| Return On Capital Employed | (2.08) | (2.18) | |
| Return On Assets | (1.24) | (1.31) | |
| Return On Equity | (1.87) | (1.96) |
Things to note about Allarity Therapeutics performance evaluation
Checking the ongoing alerts about Allarity Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Allarity Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Allarity Therapeutics generated a negative expected return over the last 90 days | |
| Allarity Therapeutics has some characteristics of a very speculative penny stock | |
| Allarity Therapeutics has high historical volatility and very poor performance | |
| Allarity Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Allarity Therapeutics currently holds 1.35 M in liabilities with Debt to Equity (D/E) ratio of 0.11, which may suggest the company is not taking enough advantage from borrowing. Allarity Therapeutics has a current ratio of 0.86, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Allarity Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (24.52 M) with loss before overhead, payroll, taxes, and interest of (36.35 M). | |
| Allarity Therapeutics currently holds about 7.73 M in cash with (17.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.75. | |
| Allarity Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Allarity Therapeutics Secures Flexible Equity Financing Facility - TipRanks |
- Analyzing Allarity Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Allarity Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Allarity Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Allarity Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Allarity Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Allarity Therapeutics' stock. These opinions can provide insight into Allarity Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Allarity Stock Analysis
When running Allarity Therapeutics' price analysis, check to measure Allarity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allarity Therapeutics is operating at the current time. Most of Allarity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allarity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allarity Therapeutics' price. Additionally, you may evaluate how the addition of Allarity Therapeutics to your portfolios can decrease your overall portfolio volatility.